NORGINE REJOINS THE UK PHARMACEUTICAL TRADE BODY ABPI

Back to media releases
Next media release
16 February 2017

CORPORATE PRESS RELEASE

NORGINE REJOINS THE UK PHARMACEUTICAL TRADE BODY ABPI

 

London. 16 February 2017, 10:00 AM GMT. Norgine B.V.‘s UK affiliate today announced that it has rejoined the UK pharmaceutical trade body, the Association of the British Pharmaceutical Industry (ABPI). 

 

In the UK Norgine employs around 770 people. Norgine employs around 400 people at its manufacturing and research site in Hengoed which makes it the largest pharma employer in Wales. At its Harefield office, Norgine employs around 370 people in UK sales and marketing, global and corporate functions.

 

Peter Martin, COO at Norgine said: “Norgine is committed to the UK and is welcoming the opportunity to work with the ABPI. The work of the ABPI is fundamental in ensuring that the interests of large and small pharmaceutical companies are well represented when leaving the EU and ultimately, to ensure that UK patients are not left behind when the rest of Europe are accessing new treatments.”

 

Norgine B.V. is also a member of  EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs and the UK Ethical Medicines Industry Group (EMIG).

 

In October 2008, Norgine resigned from the ABPI because it believed that it did not represent the interests of small specialist pharmaceutical companies.

ends

Notes to Editors:

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

 

Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine